News & Blog

NBTS Brain Tumor Clinical Trials Report: Q4 2021

It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the party responsible for enrolling patients, just follow the hyperlink.**

    • This phase II trial will study newly diagnosed adult glioblastoma or gliosarcoma patients to look at the changes in immune cells in the blood of those who take ipilimumab and nivolumab along with temozolomide.
    • This phase 0 surgical window of opportunity trial seeks to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) properties of an FDA-approved drug called Repatha (evolocumab) in patients with primary and recurrent World Health Organization (WHO) grade IV malignant glioma. The primary objective is to evaluate whether evolocumab crosses the blood-brain barrier (BBB) and is measurable in the resected tumor specimens of patients with primary and recurrent high-grade glioma or glioblastoma.
    • This trial is an open-label, multi-center phase 0 study of the drug niraparib, with an expansion phase that will enroll up to 24 participants with newly diagnosed glioblastoma and up to 18 recurrent glioma participants with IDH mutation and ATRX loss.
  • SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE) 
    • The main purpose of this phase II study is to determine whether adding SurVaxM to standard-of-care temozolomide chemotherapy is better than temozolomide treatment alone for patients with newly diagnosed glioblastoma. This study is designed to compare the length of survival in patients with newly diagnosed glioblastoma who receive temozolomide plus SurVaxM to that of patients treated with standard-of-care temozolomide plus placebo.
    • This phase I clinical trial assesses the safety of a novel personalized dendritic cell vaccine administered to glioblastoma patients shortly after completing standard-of-care treatments. 
    • The purpose of this phase II study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for glioblastoma (GBM) when given with stronger doses of routine chemotherapy.

Below is a list of phase III clinical trials that are currently enrolling patients as recorded at the close of 2021. A phase III clinical trial is traditionally the last, pivotal step in the evaluation of a potential new medicine before it is approved for use by all patients with the indicated disease.

Many of these are trials of a “novel/investigational agent” – meaning it is the first time a particular treatment is being tried for brain tumor patients. There are also a number of trials with therapies already in use for some brain tumor patients, for which researchers are evaluating these existing treatments in different combinations, different dosing regimens, and/or specific subgroups of patients.

Phase III Clinical Trials with Novel/Investigational Agents

Phase III Clinical Trials with Prior/Known Agents

*For a comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder at, where you can search potential opportunities for enrollment based on criteria specific to you.

**For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing Our patient navigation team has years of experience working closely with brain tumor patients and families. Learn more here.

Post a Comment

Your email is kept private. Required fields are marked *